Importantly, a genetic polymorphism that lowers expression of CDKN2B, which also targets CDK4/6, is significantly associated with lower eGFR, suggesting a causal relationship between increased CDK4/6 activity and human CKD. Here, CDKN2B is linked to chronic kidney disease.